NCT03359005

Irinotecan and Temozolomide for Ewing Sarcoma

Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The investigators explored the activity of vincristine and irinotecan combined with temozolomide (VIT) in patients with relapsed and metastatic Ewing Sarcoma.

Detailed description

After standard multimodal therapy, the prognosis of relapsed and metastatic Ewing Sarcoma is dismal and unchanged over the last decades. The anti-tumor activity of VIT was demonstrated by several studies in the past. However, the detailed schedule of VIT was not decided. Thus, the investigators explored the activity of 5-d shorter schedule of VIT and 5-d x2w longer schedule of VIT in patients with relapsed and metastatic Ewing Sarcoma after the failure of first-line chemotherapy with doxorubicin, vincristine, cyclophosphamide, ifosphamide and etoposide.

Conditions

• Ewing Sarcoma

Interventions

Type	Name	Description
DRUG	Vincristine	vincristine 1.5mg/m2 iv D1,D8
DRUG	Temozolomide	Temozolomide 100mg/m2/d iv on days 1-5.

Timeline

• Start date: 2018-02-07
• Primary completion: 2022-11-28
• Completion: 2025-02-28
• First posted: 2017-12-02
• Last updated: 2022-11-01

Locations

1 site across 1 country: China